Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Santhanam Ravisankar"'
Autor:
Alok Pote, Santhanam Ravisankar, Ganesh Sangle, Sunil Agarwal, Viresh Yarramshetti, Sushil Kale, M. L. A. Baig, Sambhaji Deshmukh, Ruchi Shah, Khokan Debnath, Kishor Chitalkar, Pankaj Adsare, Shahu Ingole
Background- Among the gliptins, vildagliptin is the only therapy requiring twice-daily dosing and thus adversely impacts patient adherence. To reduce dosing frequency, we developed a once-daily sustained-release (SR) vildagliptin 100 mg tablet formul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2659::b9689bedff470a92aba4df5e990f19e7
https://zenodo.org/record/4841121
https://zenodo.org/record/4841121
Autor:
Mohan Patil, Sushil Kale, Shahu Ingole, M.L.A. Baig, Sunil Kumar Agarwal, Rishi Jain, Ganesh V. Sangle, Santhanam Ravisankar, Khokan Debnath, Viresh Yarramshetti, Nitin J. Deshmukh, Alok Pote, R. D. Shah
Publikováno v:
International Journal of Research in Medical Sciences. 9:510
Background: Vildagliptin 50 mg once-daily is a clinically established anti-diabetic therapy in combination with a sulphonylurea and renally impaired patients. We developed sustained release (SR) vildagliptin 50 mg tablet formulation for prolongation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4a9af22d5c4bceda971c9324c2eec76
https://doi.org/10.18203/2320-6012.ijrms20210433
https://doi.org/10.18203/2320-6012.ijrms20210433
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.